Charles River Laboratories Intl. Inc vs Norfolk Southern Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Norfolk Southern Corporation trades at $317.79 (market cap $71.20B). The key difference: Norfolk Southern Corporation is far larger — about 5× Charles River Laboratories Intl. Inc's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Norfolk Southern Corporation for 33 Days on average.
| CRL | NSC | |
|---|---|---|
Market Cap | $14.23B | $71.20B |
Volume | 1,176,885 | 555,248 |
Sector | Health | Industrials |
52-Week High | $310.77 | $352.98 |
52-Week Low | $149.93 | $278.19 |
Typical Hold Time | 33 Days | 33 Days |
Enterprise Value | $17.06B | $86.75B |
Dividend Yield | — | 1.7% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Norfolk Southern (NSC) trades at $316.99, up 1.21% with bullish technical indicators and strong institutional support. The company demonstrates solid fundamentals with consistent earnings beats, a 21.02% net income margin, and robust cash flow from operations. Recent news highlights momentum for the proposed Union Pacific merger, with regulatory review advancing and over 500 customer endorsements supporting the combination's potential benefits.
NSC presents a favorable risk-reward profile with analyst consensus target of $361.86 offering 14% upside. Key opportunities include freight share gains from trucking and merger synergies, while risks involve fuel price pressures and regulatory hurdles for the combination. The stock remains well-positioned for long-term growth with dividend stability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →